Bartosz Chmielowski
University of California, Los Angeles
Affiliation University of California, Los Angeles Top Publications PD-1 blockade induces responses by inhibiting adaptive immune resistance (2014) – 6,802 citations Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (2016) – 3,629 citations Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (2013) – 3,435 citations Mutations Associated with Acquired Resistance ... <a title="Bartosz Chmielowski" class="read-more" href="https://journalsworld.com/researchers/bartosz-chmielowski/" aria-label="Read more about Bartosz Chmielowski">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
University of California, Los Angeles
Top Publications
- PD-1 blockade induces responses by inhibiting adaptive immune resistance (2014) - 6,802 citations
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (2016) - 3,629 citations
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (2013) - 3,435 citations
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma (2016) - 3,314 citations
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial (2015) - 2,708 citations
At a glance
- Full name
- Bartosz Chmielowski
- ORCID
- 0000-0002-2374-3320
- OpenAlex ID
- https://openalex.org/A5039301683
Research interests
- Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, Sarcoma Diagnosis and Treatment, Cutaneous Melanoma Detection and Management
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-08. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- 6,802OpenAlex citations
- 3,629OpenAlex citations
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma ↗2013 · New England Journal of Medicine3,435OpenAlex citations
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma ↗2016 · New England Journal of Medicine3,314OpenAlex citations
- 2,708OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma ↗2013 · New England Journal of Medicine
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma ↗2016 · New England Journal of Medicine
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-08 · Last data update: 2026-10-08 01:00:30
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.